![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Purpose
The present study investigated the role of free curcuminoids bioavailability on the relative radioprotective efficacy of natural unformulated curcuminoids.
Materials and Methods
A food-grade bioavailable formulation of curcuminoids as curcumagalactomannosides (CGM) and unformulated curcuminoids (UC) were employed for the study. Swiss albino mice were randomized into Normal control, Radiation control, Radiation + UC, and Radiation + CGM groups and irradiated with γ-radiation of 6, 8, 10 and 12 Gy. Survival rate, hematological and biochemical parameters, bone marrow cellularity, chromosomal aberrations and histopathology of intestine were followed as a measure of the relative efficacy.
Results and Discussion: Oral administration with both UC and CGM at 100 mg/kg. b.wt. produced significant radioprotective effect over the untreated control group of animals. However, CGM treatment was found to provide better clastogenic and genotoxic potential as compared to UC. Further, the histopathology analysis of intestine confirmed the better protective effect of CGM over UC-treated animals.
Conclusion
The present study demonstrated the positive role of the bioavailability of curcuminoids in the amelioration of radiation-induced damages in mice since CGM treatment exerted better survival rate and radioprotective effect as compared with UC, despite the relatively low concentrations of curcuminoids in CGM (39% w/w).
Ethics Approval and Consent to Participate
The study was approved by the Ethics Committee of Amala Cancer Research Center, Thrissur, India (IAEC No. 149/1999/CPCSEA).
Human and Animal Rights
No humans were involved in this study. All the animal experiments complied with the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forest, Government of India, and protocols verified and sanctioned by Institutional Animal Ethics Committee (IAEC No. 149/1999/CPCSEA).
Consent for Publication
Not applicable.
Author Contributions
Protocol design was done by KIM and RK; experiments and data collection were done by VBL and AT; data analysis and interpretation were carried out by RK, KIM, SDS, VBL and AT; manuscript was prepared by SDS and critically reviewed by RK, KIM and BM. All authors read and approved the final manuscript.
Acknowledgments
The authors are grateful to the management of Amala Cancer Research Center, Thrissur, India who conducted the animal study.
Disclosure statement
The authors disclose the following conflict of interest. “CurQfen®” is the registered trademark of CGM. AT, VBL, and RK belong to the nonprofitable university and have no conflict of interest. SDS, BM, and KIM belong to Akay Flavours & Aromatics Ltd., who provided the sample of CGM.